drugset / Trial / NCT06324812
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study was to evaluate the safety and pharmacokinetic of 611 in Chinese children and adolescents with moderate to severe atopic dermatitis.
Timeline
- Start
- 2024-07-10
- Primary completion
- 2026-05-25
- Completion
- 2026-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 611 | Monoclonal antibody | 300 mg | Subcutaneous |